{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T14:35:22Z","timestamp":1723818922130},"reference-count":30,"publisher":"Impact Journals, LLC","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2014,10,15]]},"DOI":"10.18632\/oncotarget.2424","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T23:37:56Z","timestamp":1442360276000},"page":"9295-9307","source":"Crossref","is-referenced-by-count":13,"title":["Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features"],"prefix":"10.18632","volume":"5","author":[{"given":"Elina","family":"Jokinen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Oulu, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niina","family":"Laurila","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Oulu, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peppi","family":"Koivunen","sequence":"additional","affiliation":[{"name":"Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine and Oulu Center for Cell-Matrix Research, University of Oulu, Oulu, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jussi P.","family":"Koivunen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Oulu, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2014,9,2]]},"reference":[{"issue":"3","key":"1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2012.03.003","article-title":"Cancer stem cells: impact, heterogeneity, and uncertainty","volume":"21","author":"Morrison","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrc3184","article-title":"Cancer stem cells: an evolving concept","volume":"12","author":"Eaves","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.4161\/cbt.6.11.5167","article-title":"Cancer stem cell and cancer stemloids: from biology to therapy","volume":"6","author":"Blagosklonny","year":"2007","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","article-title":"ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome","volume":"1","author":"Dontu","year":"2007","journal-title":"Cell Stem Cell"},{"issue":"8","key":"5","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1158\/0008-5472.CAN-08-4418","article-title":"Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis","volume":"69","author":"Boman","year":"2009","journal-title":"Cancer Res"},{"issue":"3","key":"6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ccr.2007.01.013","article-title":"Molecular definition of breast tumor heterogeneity","volume":"11","author":"Garber","year":"2007","journal-title":"Cancer Cell"},{"issue":"18","key":"7","first-page":"5821","article-title":"Identification of a cancer stem cell in human brain tumors","volume":"63","author":"Dirks","year":"2003","journal-title":"Cancer Res"},{"issue":"4","key":"8","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Weinberg","year":"2008","journal-title":"Cell"},{"issue":"8","key":"9","doi-asserted-by":"crossref","first-page":"e2888","DOI":"10.1371\/journal.pone.0002888","article-title":"Generation of breast cancer stem cells through epithelial-mesenchymal transition","volume":"3","author":"Puisieux","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/1078-0432.CCR-09-1630","article-title":"Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer","volume":"16","author":"Birnbaum","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"33","key":"11","doi-asserted-by":"crossref","first-page":"13820","DOI":"10.1073\/pnas.0905718106","article-title":"Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features","volume":"106","author":"Renshaw","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7120","key":"12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Rich","year":"2006","journal-title":"Nature"},{"issue":"4","key":"13","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.molcel.2012.06.014","article-title":"Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population","volume":"47","author":"Zen","year":"2012","journal-title":"Mol Cell"},{"issue":"10","key":"14","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1158\/0008-5472.CAN-12-4136","article-title":"Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells","volume":"73","author":"Miyoshi","year":"2013","journal-title":"Cancer Res"},{"issue":"4","key":"15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","article-title":"Identification of selective inhibitors of cancer stem cells by high-throughput screening","volume":"138","author":"Lander","year":"2009","journal-title":"Cell"},{"issue":"10","key":"16","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.18632\/oncotarget.707","article-title":"High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells","volume":"3","author":"Foltz","year":"2012","journal-title":"Oncotarget"},{"issue":"10","key":"17","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.18632\/oncotarget.604","article-title":"Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide","volume":"3","author":"Dunn","year":"2012","journal-title":"Oncotarget"},{"issue":"2","key":"18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrclinonc.2010.196","article-title":"Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways","volume":"8","author":"Ivy","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1158\/2159-8290.CD-12-0012","article-title":"Circumventing cancer drug resistance in the era of personalized medicine","volume":"2","author":"Janne","year":"2012","journal-title":"Cancer Discov"},{"key":"20","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/1471-2407-12-612","article-title":"Alternative dosing of dual PI3K and MEK inhibition in cancer therapy","volume":"12","author":"Koivunen","year":"2012","journal-title":"BMC Cancer"},{"issue":"23","key":"21","doi-asserted-by":"crossref","first-page":"9827","DOI":"10.1158\/0008-5472.CAN-10-1671","article-title":"Inhibition of ALK, PI3K\/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene","volume":"70","author":"Padera","year":"2010","journal-title":"Cancer Res"},{"issue":"120","key":"22","first-page":"120ra117","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers","volume":"4","author":"Engelman","year":"2012","journal-title":"Sci Transl Med"},{"issue":"18","key":"23","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","article-title":"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors","volume":"71","author":"Weremowicz","year":"2011","journal-title":"Cancer Res"},{"issue":"1","key":"24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.lungcan.2013.09.019","article-title":"Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer","volume":"83","author":"Costa","year":"2014","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"issue":"1","key":"25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1073\/pnas.0810956106","article-title":"The role of PTEN\/Akt\/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations","volume":"106","author":"Reddy","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.canlet.2012.06.010","article-title":"Highly sensitive profiling of CD44+\/CD24- breast cancer stem cells by combining global mRNA amplification and next generation sequencing: evidence for a hyperactive PI3K pathway","volume":"325","author":"Dittmer","year":"2012","journal-title":"Cancer Lett"},{"issue":"13","key":"27","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Marcoux","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"7436","key":"28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature11814","article-title":"Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance","volume":"494","author":"Stuart","year":"2013","journal-title":"Nature"},{"issue":"90","key":"29","first-page":"90ra59","article-title":"Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling","volume":"3","author":"Kris","year":"2011","journal-title":"Sci Transl Med"},{"issue":"4","key":"30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2011.07.026","article-title":"Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells","volume":"146","author":"Lander","year":"2011","journal-title":"Cell"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T10:30:21Z","timestamp":1599561021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,2]]},"references-count":30,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2014,10,15]]}},"alternative-id":["2424","25238228"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.2424","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,2]]}}}